{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:59:42Z","timestamp":1763755182683,"version":"3.45.0"},"reference-count":61,"publisher":"Oncology Nursing Society (ONS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1188\/18.cjon.e7-e17","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T10:09:36Z","timestamp":1516356576000},"page":"E7-E17","source":"Crossref","is-referenced-by-count":3,"title":["Identification and Management: Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantation"],"prefix":"10.1188","volume":"22","author":[{"given":"Mair\u00e9ad","family":"N\u00ed Chonghaile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Wolownik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Baile, W.F., Buckman, R., Lenzi, R., Glober, G., Beale, E.A., & Kudelka, A.P. (2000). SPIKES\u2014A six-step protocol for delivering bad news: Application to the patient with cancer. Oncologist, 5, 302\u2013311. https:\/\/doi.org\/10.1634\/theoncologist.5-4-302","DOI":"10.1634\/theoncologist.5-4-302"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Barker, C.C., Butzner, J.D., Anderson, R.A., ;Brant, R., & Sauve, R.S. (2003). Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 32, 79\u201387. https:\/\/doi.org\/10.1038\/sj.bmt.1704069","DOI":"10.1038\/sj.bmt.1704069"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bearman, S.I. (1995). The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood, 85, 3005\u20133020.","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005"},{"key":"4","unstructured":"Carreras, E. (2012). Early complications after HSCT. In J. Apperly, E. Carreras, E. Gluckman, & T. Masszi (Eds.), Hematopoietic stem cell transplantation (pp. 177\u2013194). Genoa, Italy: Forum Service Editore."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Carreras, E. (2015). How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. British Journal of Haematology, 168, 481\u2013491. https:\/\/doi.org\/10.1111\/bjh.13215","DOI":"10.1111\/bjh.13215"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Carreras, E., & D\u00edaz-Ricart, M. (2011). The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplantation, 46, 1495\u20131502. https:\/\/doi.org\/10.1038\/bmt.2011.65","DOI":"10.1038\/bmt.2011.65"},{"key":"7","unstructured":"Carreras, E., Bertz, H., ;Arcese, W., ;Vernant, J.P., ;Tom\u00e1s, J.F., ;Hagglund, H., . . . Apperley, J.F. (1998). Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood, 92, 3599\u20133604."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Carreras, E., D\u00edaz-Bey\u00e1, M., Rosi\u00f1ol, L., Mart\u00ednez, C., Fern\u00e1ndez-Avil\u00e9s, F., & Rovira, M. (2011). The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biology of Blood and Marrow Transplantation, 17, 1713\u20131720. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.006","DOI":"10.1016\/j.bbmt.2011.06.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Chao, N. (2014). How I treat sinusoidal obstruction syndrome. Blood, 123, 4023\u20134026. https:\/\/doi.org\/10.1182\/blood-2014-03-551630","DOI":"10.1182\/blood-2014-03-551630"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Cheuk, D.K., Wang, P., Lee, T.L., Chiang, A.K., Ha, S.Y., Lau, Y.L., ;& Chan, G.C. (2007). Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplantation, 40, 935\u2013944. https:\/\/doi.org\/10.1038\/sj.bmt.1705835","DOI":"10.1038\/sj.bmt.1705835"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Coppell, J.A., Richardson, P.G., Soiffer, R., Martin, P.L., Kernan, N.A., Chen, A., . . . Niederwieser, D. (2010). Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome. Biology of Blood and Marrow Transplantation, 16, 157\u2013168. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., . . . Bader, P. (2017). Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: A new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. Advance online publication. https:\/\/doi.org\/10.1038\/bmt.2017.161","DOI":"10.1038\/bmt.2017.161"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Corbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A., . . . Dini, G. (2012). Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial. Lancet, 379, 1301\u20131309. https:\/\/doi.org\/10.1016\/S0140-6736(11)61938-7","DOI":"10.1016\/S0140-6736(11)61938-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Corbacioglu, S., H\u00f6nig, M., Lahr, G., St\u00f6hr, S., Berry, G., Friedrich, W., & Schulz, A.S. (2006). Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplantation, 38, 547\u2013553. https:\/\/doi.org\/10.1038\/sj.bmt.1705485","DOI":"10.1038\/sj.bmt.1705485"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Cutler, C., Stevenson, K., Kim, H.T., Richardson, P., Ho, V.T., Linden, E., . . . Soiffer, R. (2008). Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood, 112, 4425\u20134431. https:\/\/doi.org\/10.1182\/blood-2008-07-169342","DOI":"10.1182\/blood-2008-07-169342"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Dalle, J.H., & Giralt, S.A. (2016). Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Risk factors and stratification, prophylaxis, and treatment. Biology of Blood and Marrow Transplantation, 22, 400\u2013409. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"17","doi-asserted-by":"crossref","unstructured":"DeLeve, L.D., Shulman, H.M., & McDonald, G.B. (2002). Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Seminars in Liver Disease, 22, 27\u201342. https:\/\/doi.org\/10.1055\/s-2002-23204","DOI":"10.1055\/s-2002-23204"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Dignan, F.L., Wynn, R.F., Hadzic, N., Karani, J., Quaglia, A., Pagliuca, A., . . . Potter, M.N. (2013). BCSH\/BSBMT guideline: Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. British Journal of Haematology, 163, 444\u2013457. https:\/\/doi.org\/10.1111\/bjh.12558","DOI":"10.1111\/bjh.12558"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Eisenberg, S. (2008). Hepatic sinusoidal obstruction syndrome in patients undergoing hematopoietic stem cell transplant. Oncology Nursing Forum, 35, 385\u2013397. https:\/\/doi.org\/10.1188\/08.ONF.385-397","DOI":"10.1188\/08.ONF.385-397"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Grupp, S.A., Smith, A.R., Triplett, B.M., Kernan, N.A., Antin, J.H., Lehmann, L., . . . Richardson, P.G. (2016). Timing of initiation of defibrotide post-diagnosis of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome post-hematopoietic stem cell transplantation: Exploratory age-group analysis from an expanded access study [Abstract]. Blood, 128, 66.","DOI":"10.1182\/blood.V128.22.66.66"},{"key":"21","doi-asserted-by":"crossref","unstructured":"H\u00e4gglund, H., Remberger, M., Klaesson, S., L\u00f6nnqvist, B., Ljungman, P., & Ringd\u00e9n, O. (1998). Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood, 92, 4568\u20134572.","DOI":"10.1182\/blood.V92.12.4568"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Hasegawa, S., Horibe, K., Kawabe, T., Kato, K., Kojima, S., Matsuyama, T., & Hirabayashi, N. (1998). Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors. Bone Marrow Transplantation, 22, 1191\u20131197. https:\/\/doi.org\/10.1038\/sj.bmt.1701506","DOI":"10.1038\/sj.bmt.1701506"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Helmy, A. (2006). Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Alimentary Pharmacology and Therapeutics, 23, 11\u201325. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02742.x","DOI":"10.1111\/j.1365-2036.2006.02742.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Ho, V.T., Linden, E., Revta, C., & Richardson, P.G. (2007). Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Review and update on the use of defibrotide. Seminars in Thrombosis and Hemostasis, 33, 373\u2013388. https:\/\/doi.org\/10.1055\/s-2007-976173","DOI":"10.1055\/s-2007-976173"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Hunt, B.J., & Jurd, K.M. (1998). Endothelial cell activation. A central pathophysiological process. BMJ, 316, 1328u\u20131329.","DOI":"10.1136\/bmj.316.7141.1328"},{"key":"26","unstructured":"Jazz Pharmaceuticals. (2016a). Defitelio (defibrotide sodium) [Package insert]. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208114lbl.pdf"},{"key":"27","unstructured":"Jazz Pharmaceuticals. (2016b). Defitelio: Summary of product characteristics. Retrieved from http:\/\/bit.ly\/2DbMGBJ"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Jones, R.J., Lee, K.S., Beschorner, W.E., Vogel, V.G., Grochow, L.B., Braine, H.G., . . . Saral, R. (1987). Venoocclusive disease of the liver following bone marrow transplantation. Transplantation, 44, 778\u2013783.","DOI":"10.1097\/00007890-198712000-00011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Kaleelrahman, M., ;Eaton, J.D., ;Leeming, D., ;Bowyer, K., ;Taberner, D., ;Chang, J., ;. . . Chopra, R. (2003). Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology, 8, 91\u201395. https:\/\/doi.org\/10.1080\/1024533031000084231","DOI":"10.1080\/1024533031000084231"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Kantarjian, H.M., DeAngelo, D.J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., . . . Advani, A.S. (2016). Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. New England Journal of Medicine, 375, 740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","DOI":"10.1056\/NEJMoa1509277"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Kashyap, A., Wingard, J., Cagnoni, P., Roy, J., Tarantolo, S., Hu, W., . . . Andersson, B.S. (2002). Intravenous versus oral busulfan as part of a busulfan\/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood and Marrow Transplantation, 8, 493\u2013500.","DOI":"10.1053\/bbmt.2002.v8.pm12374454"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Keating, G.M. (2014). Defibrotide: A review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation. Clinical Drug Investigation, 34, 895\u2013904. https:\/\/doi.org\/10.1007\/s40261-014-0242-x","DOI":"10.1007\/s40261-014-0242-x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Kumar, S., DeLeve, L.D., Kamath, P.S., & Tefferi, A. (2003). Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clinic Proceedings, 78, 589\u2013598. https:\/\/doi.org\/10.4065\/78.5.589","DOI":"10.4065\/78.5.589"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Matute-Bello, G., McDonald, G.D., Hinds, M.S., Schoch, H.G., & Crawford, S.W. (1998). Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplantation, 21, 1125\u20131130. https:\/\/doi.org\/10.1038\/sj.bmt.1701225","DOI":"10.1038\/sj.bmt.1701225"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Maximova, N., Ferrara, G., Minute, M., Pizzol, A., Kiren, V., Montico, M., . . . Tamaro, P. (2014). Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant. International Journal of Hematology, 99, 766\u2013772. https:\/\/doi.org\/10.1007\/s12185-014-1578-y","DOI":"10.1007\/s12185-014-1578-y"},{"key":"36","doi-asserted-by":"crossref","unstructured":"McDonald, G.B., Hinds, M.S., Fisher, L.D., Schoch, H.G., Wolford, J.L., Banaji, M., . . . Clift, R.A. (1993). Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Annals of Internal Medicine, 118, 255\u2013267.","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A.S., Aljurf, M., . . . Carreras, E. (2015). Sinusoidal obstruction syndrome\/veno-occlusive disease: Current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 50, 781\u2013789.","DOI":"10.1038\/bmt.2015.52"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A.S., Aljurf, M., . . . Carreras, E. (2016). Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 51, 906\u2013912.","DOI":"10.1038\/bmt.2016.130"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Morado, M., Ojeda, E., Garcia-Bustos, J., Aguado, M.J., Arrieta, R., Quevedo, E., . . . Hernandez-Navarro, F. (2000). BMT: Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology, 4, 505\u2013512.","DOI":"10.1080\/10245332.1999.11746478"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Moscard\u00f3, F., Urbano-Ispizua, A., Sanz, G.F., Brunet, S., Caballero, D., Vallejo, C., . . . Sanz, M.A. (2003). Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 31, 545\u2013550.","DOI":"10.1016\/S0301-472X(03)00070-5"},{"key":"41","unstructured":"Murali, A.R., & Carey, W.D. (2014). Liver test interpretation\u2014Approach to the patient with liver disease: A guide to commonly used liver tests. Retrieved from http:\/\/bit.ly\/2EpWyau"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Myers, K.C., Dandoy, C., El-Bietar, J., Davies, S.M., & Jodele, S. (2015). Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 21, 379\u2013381.","DOI":"10.1016\/j.bbmt.2014.09.026"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Nagler, A., Labopin, M., Gorin, N.C., Ferrara, F., Sanz, M.A., Wu, D., . . . Mohty, M. (2014). Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: A survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 99, 1380\u20131386.","DOI":"10.3324\/haematol.2014.105197"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Nurnberger, W., Michelmann, I., Burdach, S., & G\u00f6bel, U. (1998). Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Annals of Hematology, 76(2), 61\u201365.","DOI":"10.1007\/s002770050364"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Palomo, M., Mir, E., Rovira, M., Escolar, G., Carreras, E., & Diaz-Ricart, M. (2016). What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood, 127, 1719\u20131727. https:\/\/doi.org\/10.1182\/blood-2015-10-676114","DOI":"10.1182\/blood-2015-10-676114"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Rajvanshi, P., Shulman, H.M., Sievers, E.L., & McDonald, G.B. (2002). Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99, 2310\u20132314.","DOI":"10.1182\/blood.V99.7.2310"},{"key":"47","unstructured":"Richardson, P., Corbacioglu, S., Grupp, S., Hume, R., Zhu, J., Tappe, W., & Pagliuca, A. (2016). Protocol for a phase 3, randomized, adaptive study comparing the efficacy and safety of defibrotide vs best supportive care to prevent hepatic veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) in adult and pediatric patients undergoing hematopoietic stem cell transplant (HSCT). Poster session presented at the 57th Annual Meeting of the American Society of Hematology, San Diego, CA."},{"key":"48","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Corbacioglu, S., Ho, V.T., Kernan, N.A., Lehmann, L., Maguire, C., . . . Soiffer, R. (2013). Drug safety evaluation of defibrotide. Expert Opinion on Drug Safety, 12, 123\u2013136. https:\/\/doi.org\/10.1517\/14740338.2012.749855","DOI":"10.1517\/14740338.2012.749855"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Ho, V.T., Giralt, S., Arai, S., Mineishi, S., Cutler, C., . . . Soiffer, R. (2012). Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Therapeutic Advances in Hematology, 3, 253\u2013265. https:\/\/doi.org\/10.1177\/2040620712441943","DOI":"10.1177\/2040620712441943"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Riches, M.L., Kernan, N.A., Brochstein, J.A., Mineishi, S., Termuhlen, A.M., . . . Soiffer, R.J. (2016). Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 127, 1656\u20131665. https:\/\/doi.org\/10.1182\/blood-2015-10-676924","DOI":"10.1182\/blood-2015-10-676924"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Smith, A.R., Triplett, B.M., Kernan, N.A., Grupp, S.A., Antin, J.H., . . . Soiffer, R. (2017). Defibrotide for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome: Interim results from a treatment IND study. Biology of Blood and Marrow Transplantation, 23, 997\u20131004. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.008","DOI":"10.1016\/j.bbmt.2017.03.008"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Soiffer, R.J., Antin, J.H., Uno, H., Jin, Z., Kurtzberg, J., . . . Guinan, E.C. (2010). Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: A multicenter, randomized, dose-finding trial. Biology of Blood and Marrow Transplantation, 16, 1005\u20131017. https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.009","DOI":"10.1016\/j.bbmt.2010.02.009"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Sosa, E.C. (2012). Veno-occlusive disease in hematopoietic stem cell transplantation recipients. Clinical Journal of Oncology Nursing, 16, 507\u2013513. https:\/\/doi.org\/10.1188\/12.CJON.507-513","DOI":"10.1188\/12.CJON.507-513"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Strasser, S.I., & McDonald, G.B. (2009). Gastrointestinal and hepatic complications. In F.R. Appelbaum, S.J. Forman, R.S. Negrin, & K.G. Blume (Eds.), Thomas\u2019 hematopoietic cell transplantation (4th ed., pp. 1434\u20131455). Oxford, UK: Wiley-Blackwell Publishing.","DOI":"10.1002\/9781444303537.ch95"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Triplett, B.M., Kuttab, H.I., Kang, G., & Leung, W. (2015). Escalation to high dose defibrotide in patients with hepatic veno-occlusive disease. Biology of Blood and Marrow Transplantation, 21, 2148\u20132153. https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.013","DOI":"10.1016\/j.bbmt.2015.08.013"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Tsirigotis, P.D., Resnick, I.B., Avni, B., Grisariu, S., Stepensky, P., Or, R., & Shapira, M.Y. (2014). Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transplantation, 49, 1389\u20131392. https:\/\/doi.org\/10.1038\/bmt.2014.168","DOI":"10.1038\/bmt.2014.168"},{"key":"57","unstructured":"U.S. National Library of Medicine. (n.d.). Sinusoidal obstruction syndrome (veno-occlusive disease). Retrieved from https:\/\/livertox.nih.gov\/Phenotypes_sinus.html"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Wadleigh, M., Ho, V., Momtaz, P., & Richardson, P. (2003). Hepatic veno-occlusive disease: Pathogenesis, diagnosis and treatment. Current Opinion in Hematology, 10, 451\u2013462. https:\/\/doi.org\/10.1182\/blood-2003-01-0255","DOI":"10.1097\/00062752-200311000-00010"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Wadleigh, M., Richardson, P.G., Zahrieh, D., Lee, S.J., Cutler, C., Ho, V., . . . DeAngelo, D.J. (2003). Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102, 1578\u20131582. https:\/\/doi.org\/10.1182\/blood-2003-01-0255","DOI":"10.1182\/blood-2003-01-0255"},{"key":"60","unstructured":"Yamada, T. (Ed.). (2009). Textbook of gastroenterology (5th ed.). Hoboken, NJ: Wiley-Blackwell."},{"key":"61","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Chu, X., & Ruan, C. (1994). Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thrombosis and Haemostasis, 71, 507\u2013510.","DOI":"10.1055\/s-0038-1642468"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/22\/1\/identification-and-management-sinusoidal-obstruction-syndromeveno-occlusive-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:38Z","timestamp":1763754698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/22\/1\/identification-and-management-sinusoidal-obstruction-syndromeveno"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1188\/18.cjon.e7-e17","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2018,2,1]]}}}